Zobrazeno 1 - 10
of 223
pro vyhledávání: '"Keynote, A"'
Autor:
Lu Xu, Delvys Rodriguez-Abreu, Te Chun Hsia, Mehmet Ali Nahit Sendur, Perran Fulden Yumuk, A. Samkari, Irfan Cicin, Olivier Molinier, Bilal Piperdi, Keynote Investigators, Adrian Langleben, Dae Ho Lee, Balazs Medgyasszay, Francisco Orlandi, Michael Boyer, Ticiana A. Leal, Raffaele Califano, Gregory A. Otterson, Martin Reck, Keunchil Park, Nopadol Soparattanapaisarn
Publikováno v:
Journal of Clinical Oncology. 39:2327-2338
PURPOSE Pembrolizumab monotherapy is standard first-line therapy for metastatic non–small-cell lung cancer (NSCLC) with programmed death ligand 1 (PD-L1) tumor proportion score (TPS) ≥ 50% without actionable driver mutations. It is not known whet
Autor:
Radhakrishnan Ramchandren, Mieczyslaw Komarnicki, Akash Nahar, Valeria Buccheri, Patricia Marinello, John Kuruvilla, Iara Goncalves, Andrew M. McDonald, Nathalie A. Johnson, Muhit Ozcan, Michael Dickinson, Guilherme Fleury Perini, Iryna Kriachok, Ying Zhu, Neta Goldschmidt, Pier Luigi Zinzani, Armando Santoro, Ewa Paszkiewicz-Kozik, José Salvador Rodrigues de Oliveira, Robin Gasiorowski, Keynote investigators, Laura Fogliatto, Naohiro Sekiguchi
Publikováno v:
The Lancet Oncology. 22:512-524
Summary Background PD-1 blockade via pembrolizumab monotherapy has shown antitumour activity and toxicity in patients with relapsed or refractory classical Hodgkin lymphoma. Here, we present interim analyses from the KEYNOTE-204 study evaluating pemb
Autor:
SPEECH, KEYNOTE
Publikováno v:
Prosiding Seminar Nasional Hasil Penelitian Agribisnis; Vol 6, No 1 (2022): Volume 6 Tahun 2022; 1-21
KEYNOTE SPEECH
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Yeon Hee Park, Javier Cortes, Carsten Denkert, Sherko Kümmel, Jonas Bergh, Theodoros Foukakis, Fatima Cardoso, Peter Schmid, Michael Untch, Lajos Pusztai, Joyce O'Shaughnessy, Jing Zhao, Heather L. McArthur, Rina Hui, Gursel Aktan, Keynote Investigators, L. Jia, Nadia Harbeck, Peter A. Fasching, Rebecca Dent, Masato Takahashi, Vassiliki Karantza
Publikováno v:
New England Journal of Medicine. 382:810-821
Background Previous trials showed promising antitumor activity and an acceptable safety profile associated with pembrolizumab in patients with early triple-negative breast cancer. Whether ...
Autor:
Eduardo Yañez, Nicoletta Colombo, Kan Li, Vanessa Samouëlian, Alexander Arkhipov, Pamela Salman, Stephen Michael Keefe, Mahmut Gumus, M Valeria Caceres, Sarper Toker, Mivael Olivera Hurtado de Mendoza, Bradley J. Monk, Edwin Hoyos Usta, Domenica Lorusso, Vincent Castonguay, Ronnie Shapira-Frommer, Keynote Investigators, Krishnansu S. Tewari, Kosei Hasegawa, Coraline Dubot
Publikováno v:
The New England journal of medicine. 385(20)
Pembrolizumab has efficacy in programmed death ligand 1 (PD-L1)-positive metastatic or unresectable cervical cancer that has progressed during chemotherapy. We assessed the relative benefit of adding pembrolizumab to chemotherapy with or without beva
Publikováno v:
The Lancet Oncology, 22(9). Lancet Publishing Group
Autor:
Plenary and Keynote Talks
Publikováno v:
Northwestern Naturalist. 102
Autor:
Keynote investigators, John Kuruvilla
Publikováno v:
The Lancet. Oncology. 22(6)
Autor:
Hélène Senellart, Sung Bae Kim, Takashi Kojima, Antoine Adenis, Shukui Qin, Peter C. Enzinger, Jaafar Bennouna, Jia Chen, Toshihiko Doi, Jean-Philippe Metges, Ken Kato, Lin Shen, Christelle De La Fouchardiere, Kei Muro, Eric Francois, Toshikazu Moriwaki, Keynote Investigators, S. Peter Kang, Shailaja Suryawanshi, Se-Hoon Lee, Ruixue Wang, Raed Al-Rajabi, Florian Lordick, Paula Ferreira, Gustavo Girotto, Chih-Hung Hsu, Manish A. Shah, Pooja Bhagia
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 38(35)
PURPOSE Patients with advanced esophageal cancer have a poor prognosis and limited treatment options after first-line chemotherapy. PATIENTS AND METHODS In this open-label, phase III study, we randomly assigned (1:1) 628 patients with advanced/metast